Professor Mosepele Mosepele is a Research Associate with BHP since 2014. As an Infectious Disease Consultant and Clinical Epidemiologist, his research focuses on HIV-associated complications such as cardiovascular disease and immune dysregulation. Professor Mosepele is the Botswana site Principal Investigator on several protocols funded by partners in Europe and the US, including the AMBITION-cm trial (High Dose AMBISOME on a Fluconazole and Flucytosine Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomised Controlled Non-Inferiority Trial), the REPRIEVE trial (Randomized Controlled Trial of Prevention of Vascular Events in HIV) at BHP and also acts as Co- PI on a pilot study focusing on social network-level factors associated with viral suppression among HIV-infected patients at a Gaborone HIV Clinic, also at BHP. He was awarded a prestigious NIH implementation science grant in 2020, to integrate cardiovascular care cascade within existing HIV services in Botswana (InterCARE), a collaborative trial with stakeholders in the US, UK, Botswana and other countries in the SSA region. He is a committed educator with faculty position at the University of Botswana (UB) where he lectures medical students and mentors several early career researchers, both at UB and the BHP. Professor Mosepele has been working as the Deputy Coordinator for the Botswana Presidential COVID-19 Taskforce since March 2020.